Regional serotonin transporter availability and depression are correlated in Wilson?s disease

Hesse, Swen; Barthel, Henryk; Hermann, W.; Murai, Toshiya; Kluge, Regine; Wagner, A.; Sabri, Osama; Eggers, Birk

doi:10.1007/s00702-003-0008-8

Cited by 38 publications

(19 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A relationship between depressive symptoms and decreased SERT availability has been reported in several diseases, such as major depression (Malison et al 1998), seasonal affective disorders , and Wilson's disease (Hesse et al 2003). On the other hand, Dahlström et al (2000) demonstrated elevated SERT density in depressive children and adolescents.…”

Section: Discussionmentioning

confidence: 97%

Mood disorders and serotonin transporter density in ecstasy users—the influence of long-term abstention, dose, and gender

et al. 2004

View full text Add to dashboard Cite

These results suggest that ecstasy use is not associated with clinical depression (CIDI). However, the number of ecstasy tablets taken lifetime was associated with higher BDI scores for depressive mood, and this relationship seemed to persist after ecstasy use had stopped. We did not find that depressed mood in ecstasy users was associated with decrease in SERT density. Prospective studies are needed to establish the causal relationship between ecstasy use and depressed mood.

show abstract

Section: Discussionmentioning

confidence: 97%

Mood disorders and serotonin transporter density in ecstasy users—the influence of long-term abstention, dose, and gender

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Using [ 123 I] -CIT SPECT, it was found that the severity of depression was negatively correlated with the SERT availability in the thalamus/hypothalamus region [637,638]. In the midbrain, WD patients showed significantly lower SERT availability, compared to healthy controls, regardless of whether depression was evident or not [148].…”

Section: Serotonin Transporter Imaging In Neurological Diseasesmentioning

confidence: 97%

Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls

Brust¹,

Hesse²,

Müller³

et al. 2006

CPSR

View full text Add to dashboard Cite

Nuclear medicine imaging techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT) apply radiolabeled drugs that bind selectively to specific neurotransmitter receptors and transporters such as the serotonin transporter (SERT) in the living human brain. They can help overcome certain limitations of postmortem, platelet and genetic studies of the SERT. This review compares the outcome of those studies with recent neuroimaging findings. The first part of this review deals with the choice of radioligands used to quantify SERT distribution in the human brain. The second part summarizes studies performed to understand the normal physiology of the serotonergic system. Selective serotonin reuptake inhibitors (SSRIs), used to treat a wide range of neuropsychiatric disorders with emotional instability and behavioral control deficits, compete with SERT radioligands and have been investigated in pharmacological PET and SPECT studies in healthy volunteers and patients. Part three reviews SERT imaging studies in patients, which have meanwhile been performed in most disorders that benefit from SSRI treatment. It is hypothesized that serotonin deficits and neuropsychiatric symptoms are linked by the inhibition of involuntary emotional reactions to external and internal stimuli. This could explain, why the consistency of many SERT neuroimaging findings is low, and may help develop individual treatment strategies in therapy-nonresponsive cases and to engineer new drugs for the therapy of neuropsychiatric disorders.

show abstract

“…It has been reported that patients with WD express an abnormal meta bolism of neurotransmitters, particularly dopamine, noradrenaline and serotonin [8, [46][47][48][49]. Neuroimaging findings in WD suggest a complex pathogenesis involving both afferent nigrostriatal dopaminergic projections [50], loss of a dopamine transporter [51] and efferent nigrostriatal dopamin ergic projections (loss of D2 receptors in striatum) [27,52] as well as an alteration of presynaptic serotonergic transporters (SERT) availability [49].…”

Section: Discussionmentioning

confidence: 99%

“…Neuroimaging findings in WD suggest a complex pathogenesis involving both afferent nigrostriatal dopaminergic projections [50], loss of a dopamine transporter [51] and efferent nigrostriatal dopamin ergic projections (loss of D2 receptors in striatum) [27,52] as well as an alteration of presynaptic serotonergic transporters (SERT) availability [49]. Eggers et al found that the degree of depression symptoms as determined by means of the Hamilton rating scale for depression correlated negatively with the density of presynaptic SERT in 23 patients with WD [53].…”

Section: Discussionmentioning

confidence: 99%

Psychopathology and personality traits in patients with treated Wilson disease grouped according to gene mutations

Portala¹,

Waldenström²,

Knorring³

et al. 2008

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

Wilson disease (WD) is a recessively inherited copper storage disorder mainly affecting liver and brain. Genotype/phenotype correlations have been report ed but as yet not regarding psychic symptoms. Our aim was to investigate if a correlation might exist between genotype and phenotype concerning psy cho pathology and/or personality traits in patients with treated WD. Nine homozygous and three compound heterozygous Swedish patients were retrospectively investigated, representing four different mutation set tings. Psychopathological symptoms were studied using the Comprehensive Psychopathological Rating Scale (CPRS), personality traits using the Karo lin ska Scales of Personality (KSP) and mutations were analyzed by manifold sequencing. Psychopathological symptoms: Patients with the Trp779Stop mutation had the lowest scores on the total CPRS, due to less pronounced reported CPRS items, as compared to the other three groups of patients. Compound heterozygotes for the His1069Gln/ Arg1319Stop mutation show ed the highest total CPRS scores. Personality traits: Patients homozygous for the Trp779Stop and the Thr977Met mutations had high scores on Psycho pathy related scales whereas patients with His1069Gln/Arg1319Stop mutations had the lowest scores on these scales. Serum ceruloplasmin levels were undetectable in all patients with the Trp779Stop and Thr977Met mutations. The results show a trend towards a genotype/phenotype correlation regarding psychopathological symptoms and personality traits in treated patients with WD. If replicable, these results might contribute to the elucidation of the possible clinical importance of functionally deleterious gene mutations in WD psychopathology and personality traits.

show abstract

Regional serotonin transporter availability and depression are correlated in Wilson?s disease

Cited by 38 publications

References 44 publications

Mood disorders and serotonin transporter density in ecstasy users—the influence of long-term abstention, dose, and gender

Mood disorders and serotonin transporter density in ecstasy users—the influence of long-term abstention, dose, and gender

Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls

Psychopathology and personality traits in patients with treated Wilson disease grouped according to gene mutations

Contact Info

Product

Resources

About